Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
Pharvaris announced publication of Phase 3 RAPIDe-3 study results in The Lancet showing that oral deucrictibant immediate-release capsules provide rapid onset and sustained relief of hereditary angioedema (HAE) attacks with a well-tolerated safety profile. The study met all primary and secondary endpoints, supporting regulatory reviews in the U.S. …